SIRP-alpha-Fc Fusion Protein HCB101 clinical trials
Also written HCB101.
How each study uses SIRP-alpha-Fc Fusion Protein HCB101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SIRP-alpha-Fc Fusion Protein HCB101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HCB101
- 4
Studies by the year they started
4 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
FBD Biologics Limited (2) · Taipei Veterans General Hospital, Taiwan (1) · Chang Gung Memorial Hospital (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test SIRP-alpha-Fc Fusion Protein HCB101.
- Dec 2026A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)Phase 1/2 · Taipei Veterans General Hospital, Taiwan
- May 2027A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological TumorsPhase 1 · FBD Biologics Limited
Studies
Open first, then newest update. How each study uses SIRP-alpha-Fc Fusion Protein HCB101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)RecruitingPhase 1/2Taipei Veterans General Hospital, TaiwanNCT07136545Written as HCB101
- A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological TumorsRecruitingPhase 1FBD Biologics LimitedNCT05892718Written as HCB101
- The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal CancerRecruitingPhase 1/2Chang Gung Memorial HospitalNCT07204574Written as HCB101
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsActive, not recruitingPhase 1/2FBD Biologics LimitedNCT06771622Written as HCB101